ArcticZymes Technologies ASA (OSL:AZT)
Norway · Delayed Price · Currency is NOK 22.80
+0.80 (3.64%)
Feb 3, 2026, 11:09 AM CET
OSL:AZT Revenue
ArcticZymes Technologies ASA had revenue of 29.77M NOK in the quarter ending September 30, 2025, with 23.45% growth. This brings the company's revenue in the last twelve months to 109.99M, down -0.70% year-over-year. In the year 2024, ArcticZymes Technologies ASA had annual revenue of 108.11M, down -9.65%.
Revenue (ttm)
109.99M
Revenue Growth
-0.70%
P/S Ratio
10.22
Revenue / Employee
2.08M
Employees
53
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108.11M | -11.54M | -9.65% |
| Dec 31, 2023 | 119.65M | -18.02M | -13.09% |
| Dec 31, 2022 | 137.67M | 6.62M | 5.05% |
| Dec 31, 2021 | 131.05M | 33.23M | 33.96% |
| Dec 31, 2020 | 97.82M | 48.65M | 98.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aqua Bio Technology ASA | 101.51M |
| Nykode Therapeutics AS | 73.37M |
| Arctic Bioscience AS | 45.90M |
| SoftOx Solutions AS | 13.59M |
| PCI Biotech Holding ASA | 4.69M |
| Lytix Biopharma AS | 377.00K |
| Circio Holding ASA | 123.00K |
| Zelluna ASA | 53.00K |